18 citations
,
April 2011 in “Neuropharmacology” 11β-Hydroxylase inhibitors help prevent seizures in mice by boosting natural neurosteroid production.
1 citations
,
September 2025 in “PLoS ONE” Certain drugs may cause vitiligo, so patients should be monitored.
March 2021 in “Arrow - TU Dublin (Technological University Dublin)” The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.
January 1993 in “Journal of International Medical Research” The document corrects errors in previous articles, including a reversed term, updated subject weights, hair count data, and reference numbering.
November 2023 in “International Journal of Pharmaceutics” The new delivery system improves treatment for hair loss by enhancing drug absorption and effectiveness.
15 citations
,
January 2019 in “Journal of the Formosan Medical Association” Adalimumab helped control a child's severe eye disease when other treatments failed.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
November 2023 in “Children” Many pediatric epilepsy patients experience preventable severe adverse drug reactions, especially with certain medications and risk factors.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
The new method provides more accurate vibrational frequencies for drug molecules than traditional models.
January 2025 in “Drug repurposing” New drug uses show promise but need more research.
Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
1 citations
,
September 2022 in “Sudan Journal of Medical Sciences” Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.
February 2017 in “Cancer Research” Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
37 citations
,
December 2020 in “Molecules” A new delivery system makes Curcumin more effective and safer against viruses.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
51 citations
,
August 2021 in “Turkish Journal of Medical Sciences” As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.
26 citations
,
November 2016 in “European Journal of Clinical Pharmacology” Valproic acid helps delay hair loss and increases survival time for high-grade glioma patients undergoing radiation therapy.
8 citations
,
July 2023 in “Frontiers in Pharmacology” Cepharanthine shows promise as a COVID-19 treatment.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
173 citations
,
July 2012 in “British Journal of Dermatology” Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
January 2023 in “Cutaneous and Ocular Toxicology” May 2011 in “Utrecht University Repository (Utrecht University)” The nicotinamide supplement did not reduce symptoms in horses with insect bite hypersensitivity.
13 citations
,
September 2022 in “International Journal of Molecular Sciences” Five existing drugs may help fight Swine Acute Diarrhea Syndrome Coronavirus.
88 citations
,
April 2012 in “Journal of Investigative Dermatology” Blocking TRPV3 may help treat itch in dry skin conditions.
April 2011 in “Annals of Internal Medicine” Rivaroxaban and fondaparinux are effective for certain blood conditions, and hydroxyurea helps in sickle cell disease.